...
首页> 外文期刊>Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis >Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: A case report
【24h】

Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: A case report

机译:新型血小板生成素受体激动剂romiplostim与类固醇和免疫球蛋白联合使用在脾切除术前增加血小板在难治性免疫性血小板减少症中的应用:一例

获取原文
获取原文并翻译 | 示例
           

摘要

This case report describes a patient with relapsed primary immune thrombocytopenic purpura (ITP), in which splenectomy was not possible due to the persistence of a low platelet count despite treatment with corticosteroids, intravenous immunoglobulins (IVIG) and platelet transfusion treatment. As an attempt to increase platelet count prior to performing splenectomy, the thrombopoietin receptor agonist, romiplostim, was administered in combination with steroids and IVIG. A single administration of romiplostim was found to be markedly effective, allowing a rapid and notable platelet increase, required for a well tolerated splenectomy. This case confirms the potent activity of romiplostim in ITP, and indicates that patients with recurrent primary ITP who are unresponsive to conventional immunosuppressive therapy may benefit from the addition of a short course of romiplostim.
机译:该病例报告描述了一名复发性原发性免疫性血小板减少性紫癜(ITP)患者,尽管使用皮质类固醇,静脉内免疫球蛋白(IVIG)和血小板输注治疗,但由于血小板计数低仍无法进行脾切除术。为了在进行脾切除术之前增加血小板计数,将血小板生成素受体激动剂romiplostim与类固醇和IVIG联合使用。发现单次使用romiplostim效果显着,可以耐受良好的脾切除术,可迅速显着增加血小板。该病例证实了romiplostim在ITP中的有效活性,并表明对常规免疫抑制疗法无反应的复发性原发ITP患者可能会因短期服用romiplostim而受益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号